AR065847A1 - Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso. - Google Patents

Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso.

Info

Publication number
AR065847A1
AR065847A1 ARP080101222A ARP080101222A AR065847A1 AR 065847 A1 AR065847 A1 AR 065847A1 AR P080101222 A ARP080101222 A AR P080101222A AR P080101222 A ARP080101222 A AR P080101222A AR 065847 A1 AR065847 A1 AR 065847A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
cells
carrier
composition
carrier composition
Prior art date
Application number
ARP080101222A
Other languages
English (en)
Inventor
Yasuyuki Hira
Koji Nakano
Hidekazu Toyobuku
Hirofumi Takeuchi
Original Assignee
Hirofumi Takeuchi
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hirofumi Takeuchi, Otsuka Pharma Co Ltd filed Critical Hirofumi Takeuchi
Publication of AR065847A1 publication Critical patent/AR065847A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composicion portadora para la insercion de ácido nucleico, que puede insertar eficazmente un ácido nucleico en las células cuando se administra un ácido nucleico, como ser ARNip, a células de origen animal o animales, y que también posee bajatoxicidad y alta seguridad; y una composicion para la insercion de ácido nucleico que contiene la composicion portadora y ácido nucleico. Un portador para la insercion de ácido nucleico se prepara utilizando (A) una diacilfosfatidilcolina, (B) almenos un miembro seleccionado entre el grupo integrado por colesterol y sus derivados y (C) una amina primaria alifática. Asimismo, una composicion para la insercion de ácido nucleico se prepara mezclando el portador para la insercion de ácidonucleico con un ácido nucleico. Reivindicacion 13: Un método para introducir un ácido nucleico de acuerdo con la reivindicacion 12, caracterizado porque las células son células cultivadas, células separadas de organismos vivos o células existentesen organismos vivos. Reivindicacion 14: Uso de una composicion que comprende (A) una diacilfosfatidilcolina, (B) al menos un miembro seleccionado entre el grupo que comprende colesterol y sus derivados, y (C) una amina primaria alifática, en lafabricacion de un portador para la insercion de ácido nucleico.
ARP080101222A 2007-03-26 2008-03-26 Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso. AR065847A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007079944 2007-03-26

Publications (1)

Publication Number Publication Date
AR065847A1 true AR065847A1 (es) 2009-07-08

Family

ID=39788561

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101222A AR065847A1 (es) 2007-03-26 2008-03-26 Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso.

Country Status (27)

Country Link
US (1) US9315828B2 (es)
EP (1) EP2140870B1 (es)
JP (1) JP5349293B2 (es)
KR (1) KR101459391B1 (es)
CN (1) CN101646443B (es)
AR (1) AR065847A1 (es)
AU (1) AU2008230379B2 (es)
BR (1) BRPI0809634A2 (es)
CA (1) CA2682490A1 (es)
CO (1) CO6241127A2 (es)
DK (1) DK2140870T3 (es)
ES (1) ES2542864T3 (es)
HK (1) HK1139041A1 (es)
HR (1) HRP20150927T1 (es)
HU (1) HUE027053T2 (es)
IL (1) IL201116A0 (es)
MX (1) MX2009010336A (es)
MY (1) MY151450A (es)
NZ (1) NZ579804A (es)
PL (1) PL2140870T3 (es)
PT (1) PT2140870E (es)
RU (1) RU2476229C2 (es)
SI (1) SI2140870T1 (es)
TW (1) TWI428135B (es)
UA (1) UA97143C2 (es)
WO (1) WO2008117828A1 (es)
ZA (1) ZA200906576B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090912B1 (en) 2009-03-04 2015-07-28 Hirofumi Takeuchi Nucleic acid complex and nucleic acid-delivering composition
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
BR112013004585B1 (pt) 2010-09-20 2021-09-08 Merck Sharp & Dohme Corp Lipídeo catiônico, composição de lnp, e, uso de um lipídeo catiônico
JP6029131B2 (ja) * 2011-12-28 2016-11-24 国立研究開発法人国立循環器病研究センター 核酸導入剤、核酸導入方法及び細胞
WO2018112282A1 (en) 2016-12-14 2018-06-21 Ligandal, Inc. Compositions and methods for nucleic acid and/or protein payload delivery

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776488A (en) 1994-03-11 1998-07-07 Yoshitomi Pharmaceutical Industries, Ltd. Liposome preparation
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US6126964A (en) 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US6358523B1 (en) * 1996-12-06 2002-03-19 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and regulating
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
JPH10313872A (ja) 1997-05-21 1998-12-02 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス剤
JP2003510239A (ja) 1997-09-16 2003-03-18 ネクスター・ファーマシューティカルズ・インコーポレーテッド リポソームカンプトセシン製剤
US6740335B1 (en) 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
JPH11292795A (ja) * 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
EP1829856A3 (en) 1998-11-12 2009-02-25 Invitrogen Corporation Transfection reagents
CA2421409A1 (fr) * 2000-09-08 2002-03-14 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US20060030578A1 (en) 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
CN100488491C (zh) * 2002-11-21 2009-05-20 派维翁生物技术有限公司 高效融合小泡,其制备方法和含有该小泡的药物组合物
US20040208921A1 (en) * 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
KR20060036060A (ko) * 2003-06-27 2006-04-27 스미또모 가가꾸 가부시키가이샤 아미드 화합물 및 이를 사용한 식물 병해의 방제 방법
NZ544637A (en) * 2003-07-16 2010-04-30 Protiva Biotherapeutics Inc Lipid encapsulated interfering RNA
DE602004030923D1 (de) * 2003-09-17 2011-02-17 Rodos Biotarget Gmbh Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen
EP1759691A1 (en) 2003-11-20 2007-03-07 Delex Therapeutics Inc. Stable liposome compositions
AT500143A1 (de) 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
JP2005336081A (ja) 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
CA2572439A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
WO2006053430A1 (en) 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
EP2476756A1 (en) * 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
WO2007048019A2 (en) * 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
UA97559C2 (uk) 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти

Also Published As

Publication number Publication date
EP2140870A1 (en) 2010-01-06
UA97143C2 (ru) 2012-01-10
HRP20150927T1 (hr) 2015-10-09
CA2682490A1 (en) 2008-10-02
RU2009139246A (ru) 2011-05-10
RU2476229C2 (ru) 2013-02-27
ZA200906576B (en) 2010-11-24
NZ579804A (en) 2012-05-25
HK1139041A1 (en) 2010-09-10
CN101646443B (zh) 2015-01-14
MX2009010336A (es) 2009-10-16
US9315828B2 (en) 2016-04-19
JPWO2008117828A1 (ja) 2010-07-15
BRPI0809634A2 (pt) 2014-09-23
DK2140870T3 (en) 2015-07-20
AU2008230379A1 (en) 2008-10-02
WO2008117828A1 (ja) 2008-10-02
PL2140870T3 (pl) 2015-11-30
SI2140870T1 (sl) 2015-10-30
KR101459391B1 (ko) 2014-11-07
EP2140870B1 (en) 2015-06-24
PT2140870E (pt) 2015-09-15
CO6241127A2 (es) 2011-01-20
ES2542864T3 (es) 2015-08-12
HUE027053T2 (en) 2016-08-29
IL201116A0 (en) 2010-05-17
MY151450A (en) 2014-05-30
KR20090130056A (ko) 2009-12-17
TW200902035A (en) 2009-01-16
AU2008230379B2 (en) 2012-12-06
US20100063131A1 (en) 2010-03-11
EP2140870A4 (en) 2011-09-07
CN101646443A (zh) 2010-02-10
TWI428135B (zh) 2014-03-01
JP5349293B2 (ja) 2013-11-20

Similar Documents

Publication Publication Date Title
MX2022009280A (es) Vacunas de arn contra el coronavirus.
MX2020013416A (es) Compuestos de coumarina sustituidos con amina terciaria y sus usos como etiquetas fluorescentes.
AR117697A2 (es) Medios de cultivo celular
BR112013028907A2 (pt) conjugados de proteína-agente ativo e método para preparar os mesmos
TW200642700A (en) Chemically defined stabiliser
AR092487A2 (es) Anticuerpos contra la angiopoyetina 2 humana
BR112015023036A2 (pt) método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina
EA201070030A1 (ru) Синтез и применение антиинвертированных фосфоротиоатных аналогов кэп-структуры матричной phk
BR112012000942B8 (pt) processos para a produção de poliovírus, e para produzir uma vacina contra pólio
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
BR112013023757A2 (pt) método para redução de viscosidade no processo de sacarificação
GT200700058A (es) Nuevos derivados de piridazina
MX2020013384A (es) Compuestos de comarina sustituidos con amina exocíclica y sus usos como etiquetas fluorescentes.
IN2014DN03325A (es)
ECSP099296A (es) Inmuno-reguladores, preparaciones y composiciones que incluyen los inmuno-reguladores, pruebas para evaluar la actividad de los inmuno-reguladores y preparaciones y composiciones que incluyen los mismos y métodos
BR112012030959A2 (pt) emulsões acrílicas intumescíveis em álcali que compreendem ácido acrílico, seu uso em formulações aquosas e formulações que contenham as mesmas
AR065847A1 (es) Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso.
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
AR064327A1 (es) Un metodo para preparar montelukast e intermediarios utilizados en el mismo
BR112012014721A2 (pt) composição de hormônio do crescimento
BR112012028711A2 (pt) métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit
PE20140647A1 (es) Metodo para tratamiento de cancer de pulmon de celulas no pequenas
ZA202205000B (en) Cyclooctatetraene containing dyes and compositions
UY33668A (es) ?composiciones de las paredes celulares de ácido ribonucleico bacteriano, y métodos para elaborarlas y usarlas?.
UY29498A1 (es) Derivados de aminoácidos

Legal Events

Date Code Title Description
FB Suspension of granting procedure